NCT01052402已完成1 期
A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 684
- 试验地点
- 40
- 主要终点
- Frequency and severity of systemic reactions until 7 days after the first vaccination
研究概览
简要总结
The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a heterologous booster given on Day 360) of a Vero cell-derived whole virus H5N1 influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 6 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •9 to 17 years of age on the day of screening (for Stratum A only)
- •3 to 8 years of age on the day of screening (for Stratum B only)
- •6 to 35 months of age on the day of screening (for Stratum C only)
- •Subject who were born at full term of pregnancy (>= 37 weeks) with a birth weight >= 2 kg (for Stratum C only)
- •Subjects and/or their parents/legal guardians understand the nature and procedures of the study and agree to its provisions
- •Subjects´ parents/legal guardians provide written consent for participation according to national law. In case the parents/legal guardians are illiterate, the informed consent is also to be signed by an independent witness
- •Written assent according to subjects´ age and capacity of understanding
- •Subjects who are generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination
- •Subjects who are physically and mentally capable of participating in the study and follow its procedures
- •Subjects and/or their parents/legal guardians agree to keep a daily record of symptoms for the duration of the study
- •If subjects are female of childbearing potential - have a negative urine pregnancy test result within 24 hours prior to the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study
排除标准
- •History of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine
- •High risk of contracting H5N1 influenza infection (e.g. contact with poultry);
- •Subjects who currently have or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
- •Inherited or acquired immunodeficiency
- •Subjects who have a disease or are currently undergoing a form of treatment or were undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs.
- •History of severe allergic reactions or anaphylaxis
- •Rash, dermatological condition or tattoos which may interfere with injection site reaction rating
- •Subjects who have received a blood transfusion or immunoglobulins within 90 days prior to study entry
- •Subjects who have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study
- •Functional or surgical asplenia
- •Subjects with a known or suspected problem with alcohol or drug abuse
- •Subjects who were administered an investigational drug within six weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product
- •Dependent relationship with the study site personnel. Dependent relationships include close relatives (i.e., children, siblings).
- •If female: subjects wo are pregnant or lactating
结局指标
主要结局
Frequency and severity of systemic reactions until 7 days after the first vaccination
时间窗: 7 days
Rate of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by Microneutralization test >= 1:20.
时间窗: 42 days
次要结局
- Frequency and severity of systemic and injection site reactions until 21 days after the first, second and booster vaccination(Day 21, 42 and 381)
- Fever, malaise or shivering (in children and adolescents aged 3 to 17 years) and fever and irritability (in infants and young children aged 6 to 35 months) with onset within 7 days after the first, second and booster vaccination(Day 21, 42 and 381)
- Adverse events observed during the entire study period(Throughout entire study period)
- Antibody response associated with protection 21 days after the first and second vaccination, and again at 360 days after the first vaccination and 21 days after the booster vaccination(Day 21, 42, 360 and 381)
- Fold increase of antibody response 21 days after first and second vaccination as compared to baseline, and again at 21 days after the booster vaccination as compared to before the booster vaccination(Day 21, 42, 360 and 381)
- Seroconversion 21 days after the first and second vaccination and at 21 days after the booster vaccination(Day 21, 42 and 381)
研究者
研究点 (40)
Loading locations...
相似试验
进行中（未招募）
2 期
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerGastric CancerNCT05771584Aston Sci. Inc.24
招募中
1 期
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular DegenerationNCT05986864Skyline Therapeutics (US) Inc.68
已完成
1 期
A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults and elderly subjectsPrevention of COVID-19JPRN-jRCT2071200110Inoguchi Akihiro152
已完成
2 期
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsMeningococcal InfectionsMeningitisMeningococcal MeningitisNCT02199691Sanofi Pasteur, a Sanofi Company1,715
已完成
1 期
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2MalariaNCT03203421University of Oxford18